Titre:
  • Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma.
Auteur:Bachet, Jean-Baptiste; Marechal, Raphaël; Demetter, Pieter; Bonnetain, F; Couvelard, Anne; Svrcek, Magali; Bardier-Dupas, Armelle; Hammel, P; Sauvanet, Alain; Louvet, C; Paye, François; Rougier, Philippe; Penna, C; Vaillant, J C; André, T; Closset, Jean; Salmon, Isabelle; Emile, Jean-François; Van Laethem, Jean-Luc
Informations sur la publication:Annals of oncology, 23, 9, page (2327-2335)
Statut de publication:Publié, 2012-09
Sujet CREF:Sciences humaines
Mots-clés:Adjuvant chemotherapy
CXCR4
LKB1
Pancreatic adenocarcinoma
Smad4
Type II TGF-β receptor
MeSH keywords:Adenocarcinoma -- metabolism -- mortality -- secondary -- therapy
Adult
Aged
Aged, 80 and over
Chemotherapy, Adjuvant
Disease Progression
Female
Humans
Kaplan-Meier Estimate
Lymphatic Metastasis
Male
Middle Aged
Multivariate Analysis
Pancreatic Neoplasms -- metabolism -- mortality -- pathology -- therapy
Proportional Hazards Models
Prospective Studies
Receptors, CXCR4 -- metabolism
Smad4 Protein -- metabolism
Treatment Outcome
Tumor Markers, Biological -- metabolism
Note générale:Journal Article
Research Support, Non-U.S. Gov't
SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0923-7534
info:doi/10.1093/annonc/mdr617
info:pii/mdr617
info:scp/84863542976
info:pmid/22377565